Zacks Investment Research Downgrades PLx Pharma (PLXP) to Sell

PLx Pharma (NASDAQ:PLXP) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Wednesday.

According to Zacks, “PLx Pharma Inc. is a specialty pharmaceutical company. It focused on developing clinically validated and patent-protected PLxGuard(TM) delivery system to provide safe and effective aspirin products. PLx Pharma Inc., formerly known as Dipexium Pharmaceuticals Inc., is based in NEW YORK, United States. “

Separately, ValuEngine raised PLx Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd.

Shares of PLXP opened at $4.53 on Wednesday. The company has a debt-to-equity ratio of 1.53, a current ratio of 4.84 and a quick ratio of 4.84. PLx Pharma has a one year low of $1.00 and a one year high of $7.60.

PLx Pharma (NASDAQ:PLXP) last issued its quarterly earnings results on Friday, November 9th. The biotechnology company reported ($0.39) EPS for the quarter, meeting analysts’ consensus estimates of ($0.39). The company had revenue of $0.22 million for the quarter. PLx Pharma had a negative return on equity of 224.24% and a negative net margin of 12.09%. As a group, sell-side analysts expect that PLx Pharma will post -1.46 earnings per share for the current fiscal year.

In other PLx Pharma news, major shareholder Park West Asset Management Llc purchased 397,495 shares of the stock in a transaction dated Thursday, December 27th. The shares were bought at an average cost of $1.00 per share, with a total value of $397,495.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 7.22% of the stock is currently owned by company insiders.

An institutional investor recently raised its position in PLx Pharma stock. Vanguard Group Inc. increased its position in shares of PLx Pharma Inc (NASDAQ:PLXP) by 98.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 163,431 shares of the biotechnology company’s stock after acquiring an additional 80,910 shares during the period. Vanguard Group Inc. owned approximately 1.87% of PLx Pharma worth $662,000 at the end of the most recent quarter. 24.83% of the stock is owned by institutional investors.

PLx Pharma Company Profile

PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.

Read More: Asset Allocation Models, Which is Right For You?

Get a free copy of the Zacks research report on PLx Pharma (PLXP)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with's FREE daily email newsletter.

Leave a Reply